Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study.
Oksana V StanevichD S FominaI G BakulinS I GaleevE A BakinV A BelashA N KulikovA A LebedevaD A LioznovYu S PolushinI V ShlykE A VorobyevS V VorobyevaT V SurovcevaN V BakulinaM A LysenkoI S MoiseevPublished in: BMC infectious diseases (2021)
Ruxolitinib may be an alternative initial anti-cytokine therapy with comparable effectiveness in patients with potential risks of steroid administration. Patients with a high fever (≥ 38.5 °C) at admission may potentially benefit from ruxolitinib administration. Trial registration The Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness NCT04337359, CINC424A2001M, registered April, 7, 2020. First participant was recruited after registration date.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- systematic review
- chronic kidney disease
- emergency department
- early onset
- low dose
- clinical trial
- peritoneal dialysis
- human health
- stem cells
- drug induced
- climate change
- mesenchymal stem cells
- high density
- replacement therapy